Quick answers
- What is Glucagon used for?
- The FDA-approved label (Glucagon, Fresenius Kabi USA, LLC, April 1, 2022) says: “Glucagon for Injection is indicated for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract. Limitations of Use: Glucagon for Injection is not indicated for the emergency treatment of hypoglycemia because it is not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a healthcare …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Glucagon have a boxed warning?
- No. None of the 5 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Glucagon?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Glucagon been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Glucagon?
- 5 companies list prescription products of Glucagon in the FDA NDC Directory, including Xeris Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc. and Fresenius Kabi USA, LLC.
What Glucagon is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Glucagon for Injection is indicated for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract. Limitations of Use: Glucagon for Injection is not indicated for the emergency treatment of hypoglycemia because it is not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a healthcare …
— FDA label: Glucagon, Fresenius Kabi USA, LLC, effective April 1, 2022. Read the full label on DailyMed →
The FDA has 5 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 5 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, solution · Powder · Injection, powder, lyophilized, for solution |
|---|---|
| Route | Subcutaneous · Nasal · Intravenous · Intramuscular |
| Prescription products | 9 in the FDA NDC Directory |
| Brand names | Baqsimi, Gvoke Hypopen 1 Mg Auto-Injector, Gvoke Pfs 1 Mg Pre-Filled Syringe, Gvoke Vialdx, Gvoke Kit, Gvoke Hypopen 0.5 Mg Auto-Injector |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| glucagon 0.5 mg/0.1 mL injection, solution | Brand: Gvoke HypoPen 0.5 mg Auto-Injector | $3,202.85 per mL |
| glucagon 1 mg/0.2 mL injection, solution | Brand: Gvoke HypoPen 1 mg Auto-Injector | $1,595.95–$1,603.51 per mL 2 packages, lowest to highest |
| glucagon 1 mg/0.2 mL injection, solution | Brand: Gvoke Kit | $1,604.25 per mL |
| glucagon 1 mg/0.2 mL injection, solution | Brand: Gvoke PFS 1 mg Pre-filled Syringe | $1,600.41–$1,609.49 per mL 2 packages, lowest to highest |
| glucagon 3 mg powder | Brand: Baqsimi | $292.96–$293.10 per unit 2 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Xeris Pharmaceuticals, Inc.4 products
- Amphastar Pharmaceuticals, Inc.2 products
- Fresenius Kabi USA, LLC2 products
- Sportpharm LLC1 product
- American Regent, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA201849 GLUCAGON | Fresenius Kabi USA | May 8, 2015 | 8, latest September 16, 2026 2026: Labeling · 2025: Labeling · 2022: Labeling |
| NDA210134 BAQSIMI | Amphastar Pharms Inc | July 24, 2019 | 2, latest March 17, 2025 2025: Efficacy · 2020: Labeling |
| NDA212097 GVOKE HYPOPEN, GVOKE KIT, GVOKE PFS, GVOKE VIALDX | Xeris | September 10, 2019 | 5, latest March 14, 2025 2025: Efficacy · 2023: Labeling · 2021: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Glucagon, Fresenius Kabi USA, LLC, effective April 1, 2022; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →